DNA损伤
癌症研究
脱甲基酶
白血病
生物
组蛋白
突变
化疗
DNA
遗传学
基因
作者
Brenton G. Mar,S. Haihua Chu,Josephine D. Kahn,Andrei V. Krivtsov,Richard P. Koche,Cecilia A. Castellano,Jacob L. Kotlier,Rebecca L. Zon,Marie Ellen McConkey,Jonathan R. Chabon,Ryan Chappell,Peter V. Grauman,James J.-D. Hsieh,Scott A. Armstrong,Benjamin L. Ebert
出处
期刊:Blood
[Elsevier BV]
日期:2017-10-10
卷期号:130 (24): 2631-2641
被引量:152
标识
DOI:10.1182/blood-2017-03-775569
摘要
Key Points Alterations of SETD2, a histone 3 lysine 36 trimethyl (H3K36me3) transferase leads to resistance to DNA damaging-chemotherapy in leukemia. Low H3K36me3 levels impair DNA damage response and increase mutation rate, which may be targeted by H3K36me3 demethylase inhibition.
科研通智能强力驱动
Strongly Powered by AbleSci AI